Purpose: To review the results of low-intensity/high-density subthreshold micropulse laser (SDM) for treatment of central serous chorioretinopathy.
videnced by the number of recent reports, there is growing interest in subthreshold laser treatment, particularly using micropulsed lasers (MPLs), for treatment of idiopathic central serous chorioretinopathy (CSR). Subthreshold diode micropulse (SDM) laser treatment refers to using a micropulsed laser in a low-intensity/high-density treatment application paradigm. In this report, the results of SDM for CSR in a retina subspecialty practice are reviewed.
Methods
This study adhered to the tenets of the Declaration of Helsinki. The records of all patients treated in a retinal subspecialty practice with SDM for simple CSR were reviewed. Each of these cases was defined as "simple" CSR, because it was characterized by the presence of subretinal fluid and the absence of retinal edema, with active subretinal leakage due to focal/local retinal pigment epithelial (RPE) decompensation demonstrated by intravenous fundus fluorescein angiography, characteristics generally associated with a favorable therapeutic response. Applying traditional classification based on historical duration of disease, those eyes with disease for 4 months or more could be considered as "chronic," and those less than 4 months as "acute" (Table 1) . the cornea. A Mainster macular contact lens (Ocular Instruments, Mentor, OH, magnification factor ·1.05) was then applied to the cornea with viscoelastic contact solution. Contiguous spot applications of SDM laser treatment, 810 nm wavelength, 200 mm spot size, 5% duty cycle, 1.4 Watt power, 0.15 seconds duration, were applied over the area of RPE leakage and all areas of pigmentary abnormality, including the fovea if indicated, directed by the preoperative fundus fluorescein angiogram projected beside the patient (Figures 1-3) .
All patients were evaluated by clinical examination, fundus fluorescein angiography, and spectral-domain optical coherence tomography (OCT) before treatment to confirm active disease and characterize the leakage Time  F/U   1  50  M  7  100  40  407  365  453  No  Yes  1  45  2  39  M  6*  40  20  554  296  907  Yes ‡  Yes  3  38  3  39  M  3  20  20  458  303  1,290  No  Yes  1  21  4  55  F  1  25  25  314  231  295  No  Yes  1  12  5  47  F  2  20  20  489  258  484  No  Yes  1  3  6  52  M  2  30  25  647  248 Pt, patient number; PreD, duration of recent symptoms before SDM treatment; PreVA, pretreatment visual acuity as 20/X; PostVA, final visual acuity after treatment as 20/X; PreT, maximum retinal thickness, in microns, before treatment; PostT, retinal thickness, in microns, after treatment measured at same location as pretreatment maximal retinal thickness; LS, Number of SDM laser spot applications; Recur?, Recurrence of subretinal fluid; Dry, Complete resolution of subretinal fluid after treatment; Time, Time, in months, to complete resolution of subretinal fluid; F/U, length of follow-up, in months, after SDM treatment. pattern. "Enhanced depth OCT imaging" to characterize choroidal thickness was unavailable and thus not performed. 3 All treated patients underwent clinical examination and OCT at 1 month after treatment, and at various times thereafter. Repeat fundus fluorescein angiography was performed if the subretinal fluid was unimproved by 6 weeks after SDM treatment.
Results
Eleven consecutive eyes of 11 patients treated with SDM for CSR were identified for study and treated between October 2011 and April 2014 (Table 1) . They are 9 men and 2 women aged 30 years to 55 years (mean = 46). Historically, these 5 eyes could be considered chronic and 6 acute CSR.
1,2 Preoperative visual acuities ranged 20/20 to 20/100 (mean = 20/37) and preoperative maximum retinal thickness ranged 314 mm to 893 mm (mean = 508). Two eyes had previous conventional laser treatment of CSR, most recently 2 years and 5 years before SDM. Symptomatic visual loss ranged from 1 month to 7 months (mean = 3.6) before SDM treatment. The number of SDM laser spot Complete resolution of subretinal fluid after SDM was documented by OCT in all eyes. The duration from treatment to resolution of subretinal fluid ranged from 1 month to 3 months (mean = 1.3 months). One eye had recurrent leakage from a new focus of RPE decompensation at 3 months after initial SDM treatment (Figure 4) . One month later SDM was repeated, with complete resolution of subretinal fluid 3 months later. No further recurrence was noted in this eye for 35 months. In the remaining 10 eyes, a single SDM treatment was required.
Postoperative visual acuity ranged 20/15 to 20/40 (mean = 20/24), with improved visual acuity in 10 of 11 eyes (P = 0.01, paired t-test). Postoperative maximum macular thickness ranged from 222 mm to 365 mm (mean = 250) for an average 258 mm reduction in retinal thickness (P = 0.002, paired t-test). Postoperative follow-up ranged 1 month to 45 months (mean = 14). There were no adverse effects due to treatment. In particular, there was no evidence of laser-induced retinal damage on high-resolution retinal imaging.
Discussion
Central serous chorioretinopathy is a common condition of unknown etiology affecting men primarily during midlife. Usually clinically unilateral, it may be episodic, with evidence of previous subclinical disease often noted in both the affected and fellow eyes. Treatment of CSR is seldom necessary, as most cases resolve spontaneously with return of normal or near-normal visual acuity within a few weeks. In rare cases, due to visual need or accumulated damage due to previous episodes, treatment may be indicated for speedy recovery and/or minimize the risk of further macular damage that might be visually limiting and irreversible. 1, 2 In this small retrospective review of SDM for CSR, subretinal fluid resolved in all eyes with significant improvements in visual acuity and retinal thickness. Only one eye required a second treatment and this was because of recurrent exudation from a new locus of RPE leakage. There were no adverse treatment effects. Of 11 eyes, 5 eyes in this study could be considered chronic by history, and thus more resistant to treatment. However, there did not seem to be any difference in treatment response between historically acute and chronic cases in this series. This may reflect the small size of this study, the effectiveness of SDM, and/or the usefulness of the anatomical classification used in this study, compared to traditional classification based on historical chronicity.
1,2 Increased choroidal thickness by OCT enhanced depth imaging in CSR has been observed. 3 The clinical relevance of this finding remains unclear, as underscored by results of this study for which enhanced depth imaging was unavailable 3 ( Table 1 ; Figures 1-4) . A number of different effective treatments of CSR have been reported. 1 Historically, light retinal photocoagulation has been the preferred treatment, found to speed resolution of the exudative macular detachment. However, retinal photocoagulation has two principal drawbacks that have led to continued investigation of alternatives, such as scotomata resulting from the retinal damage inherent even in low-intensity retinal photocoagulation (which may also increase the risk of secondary choroidal neovascularization), and the inability to safely treat leaks near or within the fovea. [4] [5] [6] [7] [8] [9] Thus, other approaches have been investigated with the hope of avoiding the adverse effects of retinal photocoagulation, including transpupillary thermotherapy, full-fluence and reduced-fluence photodynamic therapy, and MPL. Transpupillary thermotherapy, operating at the edge of the lethal thermal threshold of the RPE, has lost favor for macular treatment because of the risk of unexpected macular infarction. 8 Full-fluence photodynamic therapy has been found to be effective for CSR, but also with a significant risk of unexpected visual loss due to macular atrophy. Reducing photodynamic therapy fluence may reduce the risk of treatment-associated visual loss, and also treatment effectiveness. Photodynamic therapy is also more invasive than other laser treatments, requiring intravenous infusion of an expensive drug contraindicated in patients with liver disease, and avoidance of sun exposure for several days. 1, 10, 11 Anti-vascular endothelial growth factor drugs have also been investigated. As one might expect in light of the mechanistic theories of CSR; and despite the expense, adverse effects (such as pain, anxiety), frequency, and risks (including endophthalmitis), only modest effectiveness of vascular endothelial growth factor inhibitors has been reported in uncomplicated CSR. 1, 2, 7, 12 In recent years, a number of studies, both retrospective and randomized, have reported use of MPLs for subthreshold treatment of CSR. These studies vary in size, laser wavelength, treatment technique (focal/local application vs. low-intensity/high-density application), and laser parameters, and in one report, a combination with indocyanine green dye infusion as an adjuvant is shown. Despite these differences, without adverse treatment effects, elimination of exudation was achieved in most cases. In controlled studies, MPL has been found to be comparable to half-fluence photodynamic therapy, superior to bevacizumab, and superior to sham in the treatment of CSR. [12] [13] [14] [15] [16] [17] [18] [19] This study is distinguished by the high number of laser spot applications per treatment session (mean = 772), and a high success rate. In previous studies, including the one previous report of SDM for CSR by Malik et al, [12] [13] [14] [15] [16] [17] [18] unsuccessful treatment was associated with fewer MPL spot applications. These observations support the theory of SDM, that a high treatment density and large coverage area maximizes the therapeutic benefits of low-intensity laser treatment and improves clinical outcomes. [20] [21] [22] The safety and effectiveness of low-intensity/highdensity MPL laser (SDM) in a number of disorders has led to interest in attempting similar effects with a short-pulsed continuous wave laser. In the one report thus far, an algorithm was used to titrate short-pulse 577 nm continuous wave laser applications to a nondamaging intensity, then applied in high-density to treat 16 eyes with CSR for 4 or more months in duration with clinical characteristics similar to those reported in this report. This low-power short-pulse continuous wave laser approach reported a lower 37% rate of single treatment success, higher 63% rate of retreatment, and lower final success rate (achieving complete resolution of subretinal fluid) of 75%. 23 Homeotrophic normalization of RPE function and retinal autoregulation by means of sublethal RPE heat-shock protein (HSP) activation (reset to default theory) has been postulated as the primary mode of action of retinal lasers. 20, 21, [24] [25] [26] [27] These findings support the hypothesis that MPL may be a more effective activator of heat-shock proteins than low-power continuous wave lasers at sublethal levels. 21 This study is limited by the small size, short followup, retrospective data collection, and single treatment center. However, the results are uniform and consistent with all previous reports of MPL for CSR. The safety, effectiveness, brevity, simplicity, repeatability, and low cost of SDM suggest SDM should be considered for treatment of CSR. The findings reported in this report suggest that treatment effectiveness may be improved by using the high-density SDM treatment paradigm. The safety of SDM allows treatment of eyes with preexisting pigment damage or laser scarring without adverse effects, unlimited retreatment, and, if necessary, direct treatment of leaks within the fovea. 20, 21, [24] [25] [26] [27] These unique facilities, the results reported previously, and those reported in this report suggest that further study of SDM laser for CSR is warranted.
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